VHL and renal cell carcinoma: Here, we took a systematic approach toward identifying co-targeting strategies for dasatinib by performing a combination drug screen using a chemogenomic library of mechanistically annotated, clinically relevant approved and investigational drugs that inhibit pathways involved in growth, metabolism, and apoptosis in human RCC cell lines that were VHL intact (wild type [WT]) and null, resulting in single-agent and dasatinib combination responses.